DUBLIN–(BUSINESS WIRE)–The “Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025” clinical trials has been added to ResearchAndMarkets.com’s offering.
The scale and scope of microbiome research activity has now become one of the fastest growing areas in biology. The relevance that it has shown for the welfare of the society and pharmaceutical industry has led to the development of a transdisciplinary environment that is however conducive to innovation with a mission to abolish the limitations in the pharmaceutical industry through excellence in microbiome research, awareness and outreach. Over the years now, gut microbiome is estimated to implicate success for the various immunotherapies.
Microbiome’s role in immunology practices is to transform world-class treatment into the medicine of today and tomorrow. It is highly recognizable that the healthcare issues that mankind is facing today is now bigger than any one solution. The treatment of certain diseases requires multiple options for the treatment and ultimately prevention. Therefore, the amalgamation of two different treatment paradigms i.e. microbiome and immunology are apparently delivering some medical benefits that millions of patients were in need for long period of time. The ways in which microbiome is understood and manipulated to serve the immunological aspects has given great interest to all the researchers.
The essential and usual concept of immunology depicts targeting the immune system of the body to provoke an immune response with huge impact but then the unsuccessful implication of immunology therapies driven treatments led to an exploration of several other basic concepts that could play an important role in boosting the immune system when combined. Looking forward, the microbiome community in the gut represented beneficial patterns with respect to further research. The area of microbiome research and its combination with immunological aspect for the disease treatment has produced a real excitement in the area of medical research and specifically microbiome research.
Companies Mentioned
- 4D Pharma
- AbbVie
- AstraZeneca plc
- Biocodex
- Bristol Mayer Squibb
- Corebiome/Diversigen
- Elogi Bioscience
- Enterome
- Ferring Pharmaceuticals
- Finch Therapeutics
- Maat Pharma
- Merck
- Microbiome Therapeutics
- Novartis
- OpenBiome
- Pfizer
- Rebiotix
- Second Genome
- Seres Therapeutics
- Symberix
- Takeda Pharmaceuticals
- Vedanta Bioscience
Report Highlights:
- Global & Regional Market Insight
- Global Human Microbiome Immunology Therapeutics Market: >US$ 1 Billion by 2025
- US Dominates Global Market Landscape: >60% Market Share
- Comprehensive Information on Ongoing Clinical Trials & Potential Drug Candidates
- Global Microbiome Modulator Drugs in Clinical Pipeline: >80 Drug in Trials
- Therapeutic Applications of Microbiome Immunology by Indication
- Clinical Trial Studies Related to Fecal Microbiota Transplant: > 250 Clinical Trials
Key Topics Covered:
1. Overview of Microbiome
2. Role of Microbiome in Human Body
3. Microbiome: Various Forms
4. Mechanism of Microbiome Activity
4.1 Nature of Immune Response
4.1.1 Immunosuppressive Activity
4.1.2 Immunostimulatory Activity
4.2 Messengers Involves in Microbiome Mechanism
4.2.1 MAMPs/PAMPs
4.2.2 Microbial Metabolites As Messengers
4.2.3 Host Cytokines As Messengers
4.2.4 Immune Cells As Messengers
5. Technological Requirement for Microbiota
5.1 Technologies Used
5.1.1 iChip
5.1.2 Simulator of the Human Intestinal Microbial Ecosystem (SHIME)
5.1.3 Gut-on-a-Chip System
5.1.4 Colonic Stem Cell Construction
5.2 Harnessing & Engineering the Microbiome
5.2.1 Additive Approaches
5.2.2 Subtractive Approaches
6. Need for Microbiome Immunology
7. Therapeutic Applications of Microbiome Immunology
7.1 Microbiome Therapy
7.2 Precision Medicine
7.3 Drug discovery
7.4 Biomarkers & Therapy Optimization
8. Human Microbiota in Infectious Diseases
8.1 Infection with Clostridium Difficile
8.2 Infection with Helicobacter Pylori
8.3 Bacterial Vaginosis
8.4 Infection with HIV
9. The Human Microbiota & Liver Diseases
9.1 Non-Alcoholic Fatty Liver Disease (NAFLD)
9.2 Alcoholic Liver Diseases (ALD)
9.3 Liver Fibrosis & Cirrhosis
10. The Human Microbiota & Metabolic Disorders
10.1 Obesity
10.2 Type 2 Diabetes
11. The Human Microbiota & Other Diseases
11.1 Microbiota & Allergic Diseases
11.2 Microbiota & Psychiatric Diseases
12. Microbiome in Immuno Oncology
12.1 Role of Microbiome in Immuno Oncology
12.2 Microbiome Mechanism in Oncogenesis & Tumor Suppression
13. Microbiome Application by Cancer Types
13.1 Gastric Cancer
13.2 Colorectal Cancer
13.3 Esophageal Cancer
13.4 Hepatocellular Carcinoma
13.5 Melanoma
13.6 Solid Tumors
14. Industrial Approaches of Microbiome Therapy in Oncology
14.1 Bacterial Approaches
14.1.1 Fecal Microbiota Transplantation (FMT)
14.1.2 Synthetic Bacteria
14.1.3 Microbial Culture
14.2 Microbiome as Vaccine
14.3 Microbiome as Small Molecules
14.4 Microbiome Therapy using Phage Virus
15. Global Human Microbiome Market Analysis
15.1 Overview
15.2 Human Microbiome Market Segmentation
15.2.1 Regional Segmentation
15.2.2 Disease Based Segmentation
15.2.3 Segmentation by Application
16. Clinical Pipeline of Microbiome Based Therapy
16.1 Microbiome Modulators in Clinical Trial
16.2 Cancer Related Clinical Trials
16.2.1 Preclinical & Discovery Phase
16.2.2 Active Clinical Trials
16.3 Clinical Trial Related To FMT
16.3.1 Clinical Trial for Recurrent C. difficile
16.3.2 Clinical Trial for Inflammatory Bowel Disease (IBD)
16.3.3 Other FMT Related Clinical Trials
17. Global Microbiome Modulators Clinical Pipeline By Company, Indication & Phase
17.1 Research
17.2 Preclinical
17.3 Clinical
17.4 Phase-I
17.5 Phase-I/II
17.6 Phase-II
17.7 Phase-II/III
17.8 Phase-III
18. Marketed Microbiome Modulators Clinical Insight
18.1 Sodium Oligomannurarate – Shanghai Green Valley Pharmaceutical
18.2 Miya-BM
19. Global Microbiome Immunology Therapeutics Market Growth Drivers
20. Microbiome Technology – Investments, Acquisitions & Collaborations by Leading Microbiome Companies
21. Blockades in the Microbiome Immunology Market
21.1 Stable Engraftment
21.2 Development of Clinically Relevant Sensors
21.3 Robustness and Evolutionary Stability of Genetic Circuits
21.4 Regulation, Safety and Biocontainment
22. Global Microbiome Immunology Market Future Panorama
23. Competitive Landscape
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/sk8m3s
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900